• News
    • News
    • Upcoming Events
    • Subscribe
  • Our Company
    • Our Story
    • Our Vision
    • CEO Statement
    • Board of Directors
    • Alzinova Team
    • Advisers & Collaborators
  • Patients & Families
    • Alzheimer's Patients
    • Impact on Society
    • The Unmet Medical Need
  • R & D
    • Alzheimer's Disease
    • Our Programs
    • Specific Targeting of Toxic Aβ Oligomers
    • The AβCC Peptide™ Technology
  • Investors
    • Overview
    • Rights Issue / Företrädesemission 2022
    • Press Releases
      • English
      • Swedish
      • Subscribe
    • Presentations
    • Company Presesentation
    • The Share
      • Share Information
      • Largest Shareholders
      • Share Capital Development
      • Rights Issues / Företrädesemissioner
      • Previous Share Issuances
      • Analyst Coverage
    • Financial Reports
      • English
      • Swedish
    • Financial Calendar
    • Corporate governance
      • General Meetings
      • Nomination Committee / Valberedning
      • Auditor
      • Articles of Association
      • Board of Directors
      • Management
    • Certified Adviser
    • IR Contact
  • Career
  • Contact
logo
  • News
    • News
    • Upcoming Events
    • Subscribe
  • Our Company
    • Our Story
    • Our Vision
    • CEO Statement
    • Board of Directors
    • Alzinova Team
    • Advisers & Collaborators
  • Patients & Families
    • Alzheimer's Patients
    • Impact on Society
    • The Unmet Medical Need
  • R & D
    • Alzheimer's Disease
    • Our Programs
    • Specific Targeting of Toxic Aβ Oligomers
    • The AβCC Peptide™ Technology
  • Investors
    • Overview
    • Rights Issue / Företrädesemission 2022
    • Press Releases
      • English
      • Swedish
      • Subscribe
    • Presentations
    • Company Presesentation
    • The Share
      • Share Information
      • Largest Shareholders
      • Share Capital Development
      • Rights Issues / Företrädesemissioner
      • Previous Share Issuances
      • Analyst Coverage
    • Financial Reports
      • English
      • Swedish
    • Financial Calendar
    • Corporate governance
      • General Meetings
      • Nomination Committee / Valberedning
      • Auditor
      • Articles of Association
      • Board of Directors
      • Management
    • Certified Adviser
    • IR Contact
  • Career
  • Contact
Home / Our Company

This is Alzinova

Alzinova AB is a Swedish clinical-stage company specializing in the treatment of Alzheimer’s disease – one of the major health scourges, without effective treatment options. The Company’s proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that with high precision could target the neurotoxic amyloid-β oligomers involved in the onset and progression of the disease.

Our Story

Alzinova is a biopharmaceutical company dedicated to developing active and passive immunotherapies to treat Alzheimer's disease. Read more

Our Vision

Learn more about Alzinova's vision and long-term goal to help Alzheimer's patients live an active and independent life. Read more

CEO Statement

Our goal is to develop a disease modifying therapeutic vaccine for the treatment of Alzheimer's disease. Read more

Board of Directors

Our Board of Directors is committed to strong corporate governance practices that promote and protect the long-term interests of our shareholders. Read more

Alzinova Team

Our management team combines in-depth industry experience and scientific expertise with strong commercial capacity. Read more

Advisers & Collaborators

Alzinova's extensive network of organisations and experts helps strengthen our capacity and reach our long-term goals. Read more

  • News
  • Our Company
  • Patients & Families
  • R & D
  • Investors
  • Contact

Alzinova AB. Pepparedsleden 1, SE-431 83, Mölndal, Sweden
+46 (0) 708 467 975   info@alzinova.com

Follow us on

follow us on linkedin